PPARα is a potential therapeutic target of drugs to treat circadian rhythm sleep disorders

Hidenori Shirai, Katsutaka Oishi, Takashi Kudo, Shigenobu Shibata, Norio Ishida

研究成果: Article

47 引用 (Scopus)

抜粋

Recent progress at the molecular level has revealed that nuclear receptors play an important role in the generation of mammalian circadian rhythms. To examine whether peroxisome proliferator-activated receptor alpha (PPARα) is involved in the regulation of circadian behavioral rhythms in mammals, we evaluated the locomotor activity of mice administered with the hypolipidemic PPARα ligand, bezafibrate. Circadian locomotor activity was phase-advanced about 3 h in mice given bezafibrate under light-dark (LD) conditions. Transfer from LD to constant darkness did not change the onset of activity in these mice, suggesting that bezafibrate advanced the phase of the endogenous clock. Surprisingly, bezafibrate also advanced the phase in mice with lesions of the suprachiasmatic nucleus (SCN; the central clock in mammals). The circadian expression of clock genes such as period2, BMAL1, and Rev-erbα was also phase-advanced in various tissues (cortex, liver, and fat) without affecting the SCN. Bezafibrate also phase-advanced the activity phase that is delayed in model mice with delayed sleep phase syndrome (DSPS) due to a Clock gene mutation. Our results indicated that PPARα is involved in circadian clock control independently of the SCN and that PPARα could be a potent target of drugs to treat circadian rhythm sleep disorders including DSPS.

元の言語English
ページ(範囲)679-682
ページ数4
ジャーナルBiochemical and Biophysical Research Communications
357
発行部数3
DOI
出版物ステータスPublished - 2007 6 8

ASJC Scopus subject areas

  • Biophysics
  • Biochemistry
  • Molecular Biology
  • Cell Biology

フィンガープリント PPARα is a potential therapeutic target of drugs to treat circadian rhythm sleep disorders' の研究トピックを掘り下げます。これらはともに一意のフィンガープリントを構成します。

  • これを引用